Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.
Prostatic Neoplasms
DRUG: CC-94676|DRUG: CC1083611|DRUG: CC1083610
Number of participants with adverse events (AEs) evaluated using the NCI CTCAE v5.0 criteria, From the time of consent at screening until 28 days after thesubject discontinues study treatment.|Dose-limiting toxicity (DLT), Up to 35 days|Non-tolerated dose (NTD), Up to 35 days|Maximum tolerated dose (MTD), Up to 35 days
Confirmed Prostate Specific Antigen (PSA) decline of â‰¥ 50% from baseline (PSA50), Up to approximately 4 years|Objective soft tissue response defined by complete response (CR) or partial response (PR) per Prostate Cancer Clinical Trials Working Group 3 (PCWG3), Up to approximately 4 years|Duration of response (DOR), Up to approximately 4 years|Proportion of participants alive and not progressed at 6 months, Up to 6 months after treatment is discontinued|PSA Progression Free Survival (PFS), Up to approximately 4 years|Radiographic progression free survival (rPFS), Up to approximately 4 years|Overall survival (OS), Up to approximately 4 years|Overall Survival (OS) rate summarized using the Kaplan-Meier method for the treated population, Up to approximately 4 years|Pharmacokinetics - Area under the plasma concentration time curve (AUC), Up to 35 days|Pharmacokinetics - Maximum plasma concentration (Cmax), Up to 35 days|Pharmacokinetics - Time to Cmax (Tmax), Up to 35 days
The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.